Feasibility and Domain Validation of Rheumatoid Arthritis (RA) Flare Core Domain Set: Report of the OMERACT 2014 RA Flare Group Plenary

REFERENCES

1. 1.↵
   1. Alten R,
   2. Pohl C,
   3. Choy EH,
   4. Christensen R,
   5. Furst DE,
   6. Hewlett SE,
   7. et al.

   Developing a construct to evaluate flares in rheumatoid arthritis: a conceptual report of the OMERACT RA Flare Definition Working Group. J Rheumatol 2011;38:1745–50.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Bingham CO 3rd,
   2. Alten R,
   3. Bartlett SJ,
   4. Bykerk VP,
   5. Brooks PM,
   6. Choy E,
   7. et al.

   Identifying preliminary domains to detect and measure rheumatoid arthritis flares: report of the OMERACT 10 RA Flare Workshop. J Rheumatol 2011;38:1751–8.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Bingham CO III,
   2. Pohl C,
   3. Alten R,
   4. Christensen R,
   5. Choy EH,
   6. Hewlett SE,
   7. et al.

   Flare and disease worsening in rheumatoid arthritis: time for a definition. Int J Adv Rheumatol 2009;7:85–91.

   OpenUrl
4. 4.↵
   1. Bykerk VP,
   2. Lie E,
   3. Bartlett SJ,
   4. Alten R,
   5. Boonen A,
   6. Christensen R,
   7. et al.

   Establishing a core domain set to measure rheumatoid arthritis flares: report of the OMERACT 11 RA flare Workshop. J Rheumatol 2014;41:799–809.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Bingham CO 3rd,
   2. Pohl C,
   3. Woodworth TG,
   4. Hewlett SE,
   5. May JE,
   6. Rahman MU,
   7. et al.

   Developing a standardized definition for disease “flare” in rheumatoid arthritis (OMERACT 9 Special Interest Group). J Rheumatol 2009;36:2335–41.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Smolen JS,
   2. Aletaha D,
   3. Bijlsma JW,
   4. Breedveld FC,
   5. Boumpas D,
   6. Burmester G,
   7. et al.

   Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631–7.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Singh JA,
   2. Furst DE,
   3. Bharat A,
   4. Curtis JR,
   5. Kavanaugh AF,
   6. Kremer JM,
   7. et al.

   2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012;64:625–39.

   OpenUrlCrossRef
8. 8.↵
   1. van der Maas A,
   2. den Broeder AA

   . Measuring flares in rheumatoid arthritis. (Why) do we need validated criteria? J Rheumatol 2014;41:189–91.

   OpenUrlFREE Full Text
9. 9.↵
   1. Hewlett S,
   2. Sanderson T,
   3. May J,
   4. Alten R,
   5. Bingham CO III,
   6. Cross M,
   7. et al.

   ‘I’m hurting, I want to kill myself’: rheumatoid arthritis flare is more than a high joint count—an international patient perspective on flare where medical help is sought. Rheumatology 2012;51:69–76.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Bartlett SJ,
    2. Hewlett S,
    3. Bingham CO 3rd,
    4. Woodworth TG,
    5. Alten R,
    6. Pohl C,
    7. et al.

    Identifying core domains to assess flare in rheumatoid arthritis: an OMERACT international patient and provider combined Delphi consensus. Ann Rheum Dis 2012;71:1855–60.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Berthelot JM,
    2. De Bandt M,
    3. Morel J,
    4. Benatig F,
    5. Constantin A,
    6. Gaudin P,
    7. et al.

    A tool to identify recent or present rheumatoid arthritis flare from both patient and physician perspectives: The ‘FLARE’ instrument. Ann Rheum Dis 2012;71:1110–6.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Bingham CO 3rd,
    2. Alten R,
    3. de Wit MP

    . The importance of patient participation in measuring rheumatoid arthritis flares. Ann Rheum Dis 2012;71:1107–9.

    OpenUrlFREE Full Text
13. 13.↵
    1. Gossec L,
    2. Dougados M,
    3. Rincheval N,
    4. Balanescu A,
    5. Boumpas DT,
    6. Canadelo S,
    7. et al.

    Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative. Ann Rheum Dis 2009;68:1680–5.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. Sanderson T,
    2. Morris M,
    3. Calnan M,
    4. Richards P,
    5. Hewlett S

    . What outcomes from pharmacologic treatments are important to people with rheumatoid arthritis? Creating the basis of a patient core set. Arthritis Care Res 2010;62:640–6.

    OpenUrlCrossRef
15. 15.↵
    1. Felson DT,
    2. Anderson JJ,
    3. Boers M,
    4. Bombardier C,
    5. Furst D,
    6. Goldsmith C,
    7. et al.

    American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727–35.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Kirwan JR,
    2. Bartlett SJ,
    3. Beaton DE,
    4. Boers M,
    5. Bosworth A,
    6. Brooks PM,
    7. et al.

    Updating the OMERACT filter: implications for patient-reported outcomes. J Rheumatol 2014;41:1011–5.

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    1. Tugwell P,
    2. Boers M,
    3. D’Agostino MA,
    4. Beaton D,
    5. Boonen A,
    6. Bingham CO 3rd,
    7. et al.

    Updating the OMERACT filter: implications of filter 2.0 to select outcome instruments through assessment of “truth”: content, face, and construct validity. J Rheumatol 2014;41:1000–4.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    1. de Vet HCW,
    2. Terwee CB,
    3. Mokkink LB,
    4. Knol DL

    . Measurement in medicine: a practical guide. Cambridge, UK: Cambridge University Press; 2011.
19. 19.↵
    1. Bykerk VP,
    2. Jamal S,
    3. Boire G,
    4. Hitchon CA,
    5. Haraoui B,
    6. Pope JE,
    7. et al.

    The Canadian Early Arthritis Cohort (CATCH): patients with new-onset synovitis meeting the 2010 ACR/EULAR classification criteria but not the 1987 ACR classification criteria present with less severe disease activity. J Rheumatol 2012;39:2071–80.

    OpenUrlAbstract/FREE Full Text
20. 20.↵
    1. van der Maas A,
    2. Lie E,
    3. Christensen R,
    4. Choy E,
    5. de Man YA,
    6. van Riel P,
    7. et al.

    Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: an OMERACT cohort validation study. Ann Rheum Dis 2013;72:1800–5.

    OpenUrlAbstract/FREE Full Text
21. 21.↵
    1. den Broeder AA,
    2. van Herwaarden N,
    3. van der Maas A,
    4. van den Hoogen FH,
    5. Bijlsma JW,
    6. van Vollenhoven RF,
    7. et al.

    Dose reduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS study. BMC Musculoskelet Disord 2013;14:299.

    OpenUrlCrossRefPubMed
22. 22.↵
    1. Orbai AM,
    2. Smith KC,
    3. Bartlett SJ,
    4. De Leon E,
    5. Bingham CO 3rd.

    “Stiffness has different meanings, I think, to everyone”: examining stiffness from the perspective of people living with rheumatoid arthritis. Arthritis Care Res 2014;66:1662–72.

    OpenUrlCrossRef
23. 23.↵
    1. Halls S,
    2. Dures E,
    3. Kirwan J,
    4. Pollock J,
    5. Baker G,
    6. Edmunds A,
    7. et al.

    Stiffness is more than just duration and severity: a qualitative exploration in people with rheumatoid arthritis. Rheumatology 2014; Sept 16 (E-pub ahead of print).
24. 24.↵
    1. Orbai AM,
    2. Halls S,
    3. Hewlett S,
    4. Bartlett S,
    5. Leong A,
    6. Bingham CO 3rd.

    More than just minutes of stiffness in the morning: report from the OMERACT rheumatoid arthritis flare group stiffness breakout sessions. J Rheumatol 2015;42:2182–4.

    OpenUrlAbstract/FREE Full Text
25. 25.↵
    1. Boers M,
    2. Idzerda L,
    3. Kirwan JR,
    4. Beaton D,
    5. Escorpizo R,
    6. Boonen A,
    7. et al.

    Toward a generalized framework of core measurement areas in clinical trials: a position paper for OMERACT 11. J Rheumatol 2014;41:978–85.

    OpenUrlAbstract/FREE Full Text